Aurobindo Pharma Limited — Important, 09-11-2024: Updates

Aurobindo Pharma reported robust Q2FY25 results with revenues of ₹7,796 crore (up 8% YoY), EBITDA of ₹1,566 crore, and a net profit of ₹817 crore, reflecting year-on-year growth of 8.6%. The company made significant strides in the US market, filing 10 ANDAs and launching 14 products. Investments primarily focused on capacity enhancements. Advances in biosimilars, peptides, and vaccines are progressing, with a scheduled soft launch of Trastuzumab in Q3.